OSE Immunotherapeutics Announces Board Changes

OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes: - Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors; - OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia; - FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes); - BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors; - OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms: - Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I; - Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO; - Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.